DK3307727T3 - Heterocykliske inhibitorer af erk1 og erk2 og deres anvendelse i behandlingen af kræft - Google Patents
Heterocykliske inhibitorer af erk1 og erk2 og deres anvendelse i behandlingen af kræft Download PDFInfo
- Publication number
- DK3307727T3 DK3307727T3 DK16741411.9T DK16741411T DK3307727T3 DK 3307727 T3 DK3307727 T3 DK 3307727T3 DK 16741411 T DK16741411 T DK 16741411T DK 3307727 T3 DK3307727 T3 DK 3307727T3
- Authority
- DK
- Denmark
- Prior art keywords
- erk2
- erk1
- cancer
- treatment
- heterocyclic inhibitors
- Prior art date
Links
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 title 1
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 title 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 title 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 title 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562175756P | 2015-06-15 | 2015-06-15 | |
PCT/US2016/037697 WO2016205418A1 (en) | 2015-06-15 | 2016-06-15 | Heterocyclic inhibitors of erk1 and erk2 and their use in the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3307727T3 true DK3307727T3 (da) | 2024-01-08 |
Family
ID=56497830
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK21156048.7T DK3842429T3 (da) | 2015-06-15 | 2016-06-15 | Heterocykliske inhibitorer af ERK1 og ERK2 og anvendelse deraf i behandling af cancer |
DK16741411.9T DK3307727T3 (da) | 2015-06-15 | 2016-06-15 | Heterocykliske inhibitorer af erk1 og erk2 og deres anvendelse i behandlingen af kræft |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK21156048.7T DK3842429T3 (da) | 2015-06-15 | 2016-06-15 | Heterocykliske inhibitorer af ERK1 og ERK2 og anvendelse deraf i behandling af cancer |
Country Status (18)
Country | Link |
---|---|
US (5) | US10751332B2 (da) |
EP (2) | EP3307727B1 (da) |
JP (2) | JP6909729B2 (da) |
KR (2) | KR102644798B1 (da) |
CN (2) | CN113200961B (da) |
AU (2) | AU2016280717C1 (da) |
BR (1) | BR112017026159A2 (da) |
CA (1) | CA2986587C (da) |
DK (2) | DK3842429T3 (da) |
ES (2) | ES2968007T3 (da) |
FI (1) | FI3307727T3 (da) |
IL (1) | IL255613B (da) |
MX (2) | MX2017014584A (da) |
PL (1) | PL3842429T3 (da) |
PT (2) | PT3842429T (da) |
RU (1) | RU2017139727A (da) |
WO (1) | WO2016205418A1 (da) |
ZA (1) | ZA201707526B (da) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3307727B1 (en) | 2015-06-15 | 2023-10-04 | Asana BioSciences, LLC | Heterocyclic inhibitors of erk1 and erk2 and their use in the treatment of cancer |
JP6931646B2 (ja) | 2015-10-21 | 2021-09-08 | 大塚製薬株式会社 | ベンゾラクタム化合物 |
GB201706327D0 (en) * | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
BR112019024007A2 (pt) * | 2017-05-16 | 2020-07-07 | Biomed Valley Discoveries, Inc. | composições e métodos para tratamento do câncer com mutações atípicas do braf |
JP2021525783A (ja) | 2018-06-08 | 2021-09-27 | 貝達薬業股▲ふん▼有限公司Betta Pharmaceuticals Co.,Ltd | Erk阻害剤及びその使用 |
CN109608444B (zh) * | 2018-11-27 | 2022-02-11 | 中国药科大学 | 含异吲哚啉酮的erk抑制剂及其制备方法与用途 |
TW202102511A (zh) | 2019-03-28 | 2021-01-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 噻吩并雜環類衍生物、其製備方法及其在醫藥上的應用 |
EP3950690A4 (en) * | 2019-03-29 | 2022-12-07 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | PYRROLOHETEROCYCLIC DERIVATIVE, PROCESS FOR PRODUCTION THEREOF AND APPLICATION THEREOF IN MEDICINE |
EP4051264A1 (en) * | 2019-10-28 | 2022-09-07 | Asana BioSciences, LLC | Improved methods, kits, compositions and dosing regimens for the use of heterocyclic inhibitors of erk1 and erk2 |
CN111620860B (zh) * | 2020-06-23 | 2023-02-03 | 济南健丰化工有限公司 | 一种福瑞塞替的制备方法 |
CN114315837B (zh) * | 2020-09-29 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | 一种erk抑制剂的结晶形式及其制备方法 |
AU2021354821A1 (en) * | 2020-09-29 | 2023-06-08 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Crystal form of pyrrolo heterocyclic derivative and preparation method therefor |
CA3215387A1 (en) * | 2021-04-16 | 2022-10-20 | Dawei XUAN | Uses of heterocyclic inhibitors of erk1/2 |
WO2022271939A1 (en) * | 2021-06-24 | 2022-12-29 | Erasca, Inc. | Erk1/2 and cdk4/6 inhibitors combination therapy |
AU2022300368A1 (en) * | 2021-06-24 | 2024-01-18 | Erasca, Inc. | Erk1/2 and shp2 inhibitors combination therapy |
CA3223602A1 (en) * | 2021-06-24 | 2022-12-29 | Robert Field SHOEMAKER | Erk1/2 and kras g12c inhibitors combination therapy |
WO2022271919A1 (en) * | 2021-06-24 | 2022-12-29 | Erasca, Inc. | Erk1/2 or shp2 inhibitors and flt3 inhibitors combination therapy |
TW202341999A (zh) * | 2022-03-28 | 2023-11-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 吡咯并雜環類衍生物的富馬酸鹽的晶型及其製備方法 |
WO2024064690A1 (en) * | 2022-09-20 | 2024-03-28 | Erasca, Inc. | Erk1/2 inhibitor polymorph forms |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1319849B1 (it) | 2000-02-18 | 2003-11-03 | Angelo Dotta | Cerotto in confezione ad apertura rapida e mezzi per la realizzazionedella stessa. |
MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
US6743941B2 (en) | 2001-06-15 | 2004-06-01 | Aventis Pharma Deutschland Gmbh | Process for the production of piperidine derivatives |
US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
WO2005068468A2 (en) * | 2003-12-02 | 2005-07-28 | Vertex Pharmaceuticals, Inc. | Heterocyclic protein kinase inhibitors and uses thereof |
US20070191336A1 (en) | 2003-12-24 | 2007-08-16 | Flynn Daniel L | Anti-inflammatory medicaments |
CA2566444A1 (en) * | 2004-05-14 | 2005-12-01 | Vertex Pharmaceuticals Incorporated | Prodrugs of pyrrolylpyrimidine erk protein kinase inhibitors |
WO2006071644A1 (en) * | 2004-12-23 | 2006-07-06 | Vertex Pharmaceuticals Incorporated | Selective inhibitors of erk protein kinases and uses therof |
US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
MY160820A (en) * | 2009-11-13 | 2017-03-31 | Genosco | Kinase inhibitors |
US8691861B2 (en) | 2011-04-13 | 2014-04-08 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
US9227969B2 (en) * | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
EP3307727B1 (en) | 2015-06-15 | 2023-10-04 | Asana BioSciences, LLC | Heterocyclic inhibitors of erk1 and erk2 and their use in the treatment of cancer |
EP3471717A4 (en) | 2016-06-20 | 2020-01-22 | Kura Oncology, Inc. | TREATMENT OF SKIN CELL CARCINOMAS USING ERK INHIBITORS |
WO2020046966A1 (en) | 2018-08-27 | 2020-03-05 | Kura Oncology, Inc. | Treatment of adenocarcinomas with mapk pathway inhibitors |
EP4051264A1 (en) | 2019-10-28 | 2022-09-07 | Asana BioSciences, LLC | Improved methods, kits, compositions and dosing regimens for the use of heterocyclic inhibitors of erk1 and erk2 |
CA3215387A1 (en) | 2021-04-16 | 2022-10-20 | Dawei XUAN | Uses of heterocyclic inhibitors of erk1/2 |
-
2016
- 2016-06-15 EP EP16741411.9A patent/EP3307727B1/en active Active
- 2016-06-15 PT PT211560487T patent/PT3842429T/pt unknown
- 2016-06-15 US US15/183,504 patent/US10751332B2/en active Active
- 2016-06-15 KR KR1020217005104A patent/KR102644798B1/ko active IP Right Grant
- 2016-06-15 CN CN202110399513.4A patent/CN113200961B/zh active Active
- 2016-06-15 KR KR1020177034157A patent/KR102644788B1/ko active IP Right Grant
- 2016-06-15 ES ES16741411T patent/ES2968007T3/es active Active
- 2016-06-15 CN CN201680031963.5A patent/CN107922387A/zh active Pending
- 2016-06-15 DK DK21156048.7T patent/DK3842429T3/da active
- 2016-06-15 WO PCT/US2016/037697 patent/WO2016205418A1/en active Application Filing
- 2016-06-15 EP EP21156048.7A patent/EP3842429B1/en active Active
- 2016-06-15 PL PL21156048.7T patent/PL3842429T3/pl unknown
- 2016-06-15 MX MX2017014584A patent/MX2017014584A/es unknown
- 2016-06-15 CA CA2986587A patent/CA2986587C/en active Active
- 2016-06-15 FI FIEP16741411.9T patent/FI3307727T3/fi active
- 2016-06-15 DK DK16741411.9T patent/DK3307727T3/da active
- 2016-06-15 PT PT167414119T patent/PT3307727T/pt unknown
- 2016-06-15 AU AU2016280717A patent/AU2016280717C1/en active Active
- 2016-06-15 US US15/183,486 patent/US9896445B2/en active Active
- 2016-06-15 BR BR112017026159-6A patent/BR112017026159A2/pt not_active Application Discontinuation
- 2016-06-15 ES ES21156048T patent/ES2930050T3/es active Active
- 2016-06-15 RU RU2017139727A patent/RU2017139727A/ru not_active Application Discontinuation
- 2016-06-15 JP JP2017559575A patent/JP6909729B2/ja active Active
-
2017
- 2017-09-01 US US15/694,124 patent/US10471051B2/en active Active
- 2017-11-07 ZA ZA2017/07526A patent/ZA201707526B/en unknown
- 2017-11-12 IL IL255613A patent/IL255613B/en active IP Right Grant
- 2017-11-14 MX MX2021000148A patent/MX2021000148A/es unknown
-
2020
- 2020-02-13 US US16/790,082 patent/US11103491B2/en active Active
- 2020-11-19 AU AU2020273302A patent/AU2020273302B2/en active Active
-
2021
- 2021-03-16 JP JP2021042239A patent/JP7093438B2/ja active Active
- 2021-07-06 US US17/368,559 patent/US11925629B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3307727T3 (da) | Heterocykliske inhibitorer af erk1 og erk2 og deres anvendelse i behandlingen af kræft | |
DK3678668T3 (da) | ENPP1-inhibitorer og deres anvendelse til behandling af kræft | |
DK3285809T3 (da) | Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner. | |
DK3558997T3 (da) | Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer | |
DK3368069T3 (da) | Anvendelse af myostatininhibitorer og kombinationsterapier | |
DK3389658T3 (da) | Glycosidasehæmmere og anvendelser deraf | |
DK3371152T3 (da) | Sammensætninger omfattende en hæmmer af lysinspecifik demethylase-1 med en pyrimidinring og anvendelse deraf i behandling af cancer | |
DK3277681T3 (da) | Imidazolonylquinoliner og deres anvendelse som atm-kinaseinhibitorer | |
DK3452485T3 (da) | Arginasehæmmere og deres terapeutiske anvendelser | |
DK3612517T3 (da) | Bicykliske forbindelser og deres anvendelse ved behandling af cancer | |
DK3212226T3 (da) | Sammensætninger og anvendelsesfremgangsmåder til behandling af metaboliske lidelser | |
DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
DK3076972T3 (da) | Cancerbehandling med kombination af plinabulin og taxan | |
DK3204497T3 (da) | Terapeutisk hæmning af lactatdehydrogenase og midler dertil | |
DK3303339T3 (da) | Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme | |
DK3576738T3 (da) | Gaboxadolmonohydrat i behandling af tinnitus | |
DK3621694T3 (da) | Lrrc33-inhibitorer og anvendelse heraf | |
DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
DK3273995T3 (da) | Kombineret anvendelse af alginatoligomerer og cftr-modulatoren lumacaftor i behandlingen af tilstande associeret med cftr-dysfunktion | |
DK3722291T3 (da) | Indolinonforbindelser og deres anvendelse i behandlingen af fibrotiske sygdomme | |
DK3790879T3 (da) | Triazolopyrimidinforbindelser og deres anvendelse til behandling af kræft | |
DK3426243T3 (da) | 3-phosphoglyceratdehydrogenase-inhibitorer og anvendelser deraf | |
DK3200748T3 (da) | Sammensætninger og fremgangsmåder til behandling og profylakse af infektioner på operationssted | |
DK3142655T3 (da) | Sammensætninger og fremgangsmåder til behandling af hjertefibrose med ifetroban | |
DK3474883T3 (da) | Komplementinhibitorer og anvendelser deraf |